0.3386
Cosmos Health Inc stock is traded at $0.3386, with a volume of 2.71M.
It is up +6.54% in the last 24 hours and up +52.87% over the past month.
Cosmos Health Inc is a diversified, vertically integrated healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research & development of medicines and repurposing drugs as well as operator of a telehealth platform. The company has developed its own proprietary branded nutraceutical products, named 'Sky Premium Life' and 'Mediterranation'. Its product portfolio includes generics and over-the-counter pharmaceutical products, medicines, as well as nutraceuticals and biocides. The company's Reportable segments are Wholesale, Pharma manufacturing, and Nutraceutical and pharmaceuticals, with the majority of revenue generated from the Wholesale segment.
See More
Previous Close:
$0.3178
Open:
$0.335
24h Volume:
2.71M
Relative Volume:
0.29
Market Cap:
$34.07M
Revenue:
$69.49M
Net Income/Loss:
$-21.13M
P/E Ratio:
-0.5217
EPS:
-0.649
Net Cash Flow:
$-14.46M
1W Performance:
+25.73%
1M Performance:
+52.87%
6M Performance:
-1.80%
1Y Performance:
-64.48%
Cosmos Health Inc Stock (COSM) Company Profile
Name
Cosmos Health Inc
Sector
Industry
Phone
312-536-3102
Address
5 AGIOU GEORGIOU, PILEA, THESSALONIKI
Compare COSM vs MCK, COR, CAH, HSIC, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
COSM
Cosmos Health Inc
|
0.3386 | 25.52M | 69.49M | -21.13M | -14.46M | -0.649 |
|
MCK
Mckesson Corp
|
886.47 | 102.78B | 403.43B | 5.10B | 5.41B | 38.47 |
|
COR
Cencora Inc
|
316.49 | 61.36B | 328.68B | 2.55B | 1.56B | 13.03 |
|
CAH
Cardinal Health Inc
|
225.75 | 54.56B | 250.74B | 1.55B | 4.39B | 6.5398 |
|
HSIC
Henry Schein Inc
|
85.20 | 9.85B | 13.38B | 418.00M | 391.00M | 3.3112 |
|
AHG
Akso Health Group Adr
|
0.76 | 718.95M | 14.85M | -136.07M | 7.25M | -0.4726 |
Cosmos Health Inc Stock (COSM) Latest News
Cosmos Health subsidiary secures 5-year manufacturing deal By Investing.com - Investing.com South Africa
Cosmos Health Secures Additional 2.5 Mln Units Under New Five-Year Contract Manufacturing Deal With Viofar - TradingView
COSM Looks 10.4% Undervalued on GF Value™ Amid Contract Manufact - GuruFocus
Cosmos Health Unit Enters 5-Year Contract Manufacturing Deal With Viofar Over Cardiovascular Medicine - Bitget
Cosmos Health subsidiary secures 5-year manufacturing deal - Investing.com
Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units - ACCESS Newswire
Cosmos Health Launches C-ScrubVet in the UK, Advancing into the $69 Billion Global Animal Health Market - webull.com
COSM Looks 8.2% Undervalued on GF Value™ Amid Challenging Fundam - GuruFocus
Cosmos Health receives first orders for veterinary product line - Investing.com
Cosmos Health buyback reaches 5.11 million shares under $5 million program - scanx.trade
Why Did SOC, HTZ, COSM Stocks Tumble To 52-Week Lows? - Stocktwits
Cosmos Health reports record revenue, retires $8M debt early By Investing.com - Investing.com Australia
Cosmos Health: A Company Transformed — 2026 Y - Moomoo
Cosmos Health Reaffirms 2029 Guidance - TradingView
Cosmos Health Q2FY26 Results: Revenue up 28.8% to $18.99M - scanx.trade
Cosmos Health reports record revenue, retires $8M debt early - Investing.com
Cosmos Health Inc. - Via Ritzau
Cosmos Health Strengthens Balance Sheet and Streamlines Capital Structure, Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution from Conversions - marketscreener.com
Cosmos Health stock rises after $8 million note retirement - AD HOC NEWS
Cosmos Health retires $8M convertible note early By Investing.com - Investing.com UK
Cosmos Health Strengthens Balance Sheet and Streamlines Capital Structure; Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution From Conversions - kommunikasjon.ntb.no
COSMOS HEALTH INC: OPERATING CASH REQUIREMENTS REDUCED BY MORE THAN 30% - Moomoo
Cosmos Health projects $6M revenue from Oliv18 supplement launch - Investing.com India
COSM Looks 33.4% Undervalued on GF Value™ Despite Weak Fundamentals - GuruFocus
Cosmos Health projects $6M revenue from Oliv18 supplement launch By Investing.com - Investing.com Nigeria
Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories - Barchart.com
Weekly Recap: Cosmos Health Q2 revenue gains and five‑year Innova Saudi deal - TradingView
Cosmos Health Inc (COSM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cosmos Health C-Sept PRO sales exceed $1.3 million at 72% margin - scanx.trade
Is Cosmos Health Inc (COSM) Undervalued After Q2 Earnings Miss? GF Score: 29/100, Revenue at $18.99 Million - GuruFocus
Cosmos Reports Record Q2: Revenue $19.0M, H1 $36.9M; Adjusted Gross Profit Up 58% - TradingView
Cosmos Health Company Profile & Introduction - Moomoo
COSM Looks 40.0% Undervalued on GF Value™ Amid Distribution Deal - GuruFocus
Cosmos Health signs exclusive Saudi distribution deal for supplements By Investing.com - Investing.com South Africa
Cosmos Health Enters Saudi Arabia Through Exclusive Distribution Deal With Innova Healthcare - TradingView
Cosmos Health signs exclusive Saudi distribution deal for supplements - Investing.com
Cosmos Health Secures Exclusive Saudi Arabia Distribution Agreement for Sky Premium Life with Innova Healthcare - Quiver Quantitative
Cosmos Health Enters Saudi Arabia Through Exclusive Distribution Agreement With Innova Healthcare; Secures Initial Purchase Order of 126,000 Sky Premium Life Units, With More Than 5 Million Units Expected Over Initial 5-Year Term - Yahoo Finance
COSM Looks 43.9% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
MSN Money - MSN
Cosmos (COSM) Latest Quarter: The EPS Result Is Below Expectation in the Reported Period; Closing Reaction: The Stock Loses 6.20% in the Current UpdateAdjusted Earnings Analysis - Vinanet
Cosmos Health reports record Q2 revenue of $19 million By Investing.com - Investing.com Nigeria
Cosmos Health reports record Q2 revenue of $19 million, up 29% - Investing.com Nigeria
Cosmos Health Q2 Results: EPS Misses Estimate, Sales Rise 29% YoY - scanx.trade
Cosmos Health Reports Q2 2026 - TradingView
Cosmos Health Reports Record Q2 and First-Half 2026 Revenue, Exceeds $75 Million Adjusted Annualized Run-Rate - Quiver Quantitative
BRIEF-Cosmos Health Q2 Gross Profit USD 1.51 Million - TradingView
Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway - marketscreener.com
Press Release: Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Progra - Moomoo
Cosmos Health(COSM) Stock Options Chain | Quotes & News - Moomoo
Cosmos Health reports record Q2 revenue of $19 million - Investing.com
Cosmos Health Inc Stock (COSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cosmos Health Inc Stock (COSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Siokas Grigorios | Chief Executive Officer |
Jul 29 '26 |
Buy |
0.18 |
766,284 |
140,000 |
14,248,092 |
| Terzis Georgios | Chief Financial Officer |
Jun 16 '26 |
Buy |
0.25 |
168,135 |
42,000 |
2,235,398 |
| Siokas Grigorios | Chief Executive Officer |
Jun 11 '26 |
Buy |
0.21 |
218,447 |
45,000 |
13,481,808 |
| Siokas Grigorios | Chief Executive Officer |
Jun 10 '26 |
Buy |
0.23 |
701,447 |
160,000 |
13,263,361 |
| Siokas Grigorios | Chief Executive Officer |
Feb 12 '26 |
Buy |
0.37 |
388,532 |
145,000 |
8,861,914 |
| Siokas Grigorios | Chief Executive Officer |
Feb 11 '26 |
Buy |
0.41 |
291,262 |
120,000 |
8,473,382 |
| Siokas Grigorios | Chief Executive Officer |
Jan 23 '26 |
Buy |
0.50 |
90,325 |
45,000 |
8,182,120 |
| Siokas Grigorios | Chief Executive Officer |
Jan 20 '26 |
Buy |
0.50 |
353,321 |
175,000 |
8,091,795 |
| Siokas Grigorios | Chief Executive Officer |
Jan 14 '26 |
Buy |
0.45 |
493,495 |
220,000 |
7,738,474 |
| Siokas Grigorios | Chief Executive Officer |
Jan 12 '26 |
Buy |
0.50 |
113,185 |
57,000 |
7,244,979 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):